Mannatech (MTEX) Competitors $8.83 -0.31 (-3.39%) Closing price 03/28/2025 03:50 PM EasternExtended Trading$8.57 -0.26 (-2.89%) As of 03/28/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. ASRT, THTX, ANRO, SKYE, ALGS, ADAP, ENTX, IMAB, EPIX, and ALTSShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Assertio (ASRT), Theratechnologies (THTX), Alto Neuroscience (ANRO), Skye Bioscience (SKYE), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Entera Bio (ENTX), I-Mab (IMAB), ESSA Pharma (EPIX), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Assertio Theratechnologies Alto Neuroscience Skye Bioscience Aligos Therapeutics Adaptimmune Therapeutics Entera Bio I-Mab ESSA Pharma Janone Mannatech (NASDAQ:MTEX) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Do analysts prefer MTEX or ASRT? Assertio has a consensus price target of $2.75, indicating a potential upside of 297.57%. Given Assertio's stronger consensus rating and higher probable upside, analysts clearly believe Assertio is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of MTEX or ASRT? 13.0% of Mannatech shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 41.5% of Mannatech shares are owned by company insiders. Comparatively, 3.2% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, MTEX or ASRT? Mannatech has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$121.55M0.14-$2.24M$1.336.64Assertio$124.96M0.53-$331.94M-$0.23-3.01 Which has more risk and volatility, MTEX or ASRT? Mannatech has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Does the media prefer MTEX or ASRT? In the previous week, Mannatech had 2 more articles in the media than Assertio. MarketBeat recorded 3 mentions for Mannatech and 1 mentions for Assertio. Assertio's average media sentiment score of 1.89 beat Mannatech's score of 0.72 indicating that Assertio is being referred to more favorably in the news media. Company Overall Sentiment Mannatech Positive Assertio Very Positive Does the MarketBeat Community prefer MTEX or ASRT? Mannatech received 211 more outperform votes than Assertio when rated by MarketBeat users. Likewise, 77.22% of users gave Mannatech an outperform vote while only 59.68% of users gave Assertio an outperform vote. CompanyUnderperformOutperformMannatechOutperform Votes32277.22% Underperform Votes9522.78% AssertioOutperform Votes11159.68% Underperform Votes7540.32% Is MTEX or ASRT more profitable? Mannatech has a net margin of -1.26% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Mannatech's return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-1.26% -15.62% -3.76% Assertio -54.46%3.79%1.81% SummaryAssertio beats Mannatech on 10 of the 18 factors compared between the two stocks. Remove Ads Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.22M$1.12B$5.63B$7.84BDividend YieldN/AN/A5.33%4.01%P/E Ratio-10.909.4023.5518.73Price / Sales0.145.68388.2390.77Price / CashN/A10.4038.1734.64Price / Book1.571.206.894.23Net Income-$2.24M-$53.09M$3.20B$247.47M7 Day Performance-8.97%-3.03%-3.06%-2.29%1 Month Performance-21.86%-16.62%1.51%-5.81%1 Year Performance7.42%-42.23%9.37%-0.96% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech0.7014 of 5 stars$8.83-3.4%N/A+7.4%$17.22M$121.55M-10.90250Earnings ReportAnalyst ForecastGap DownASRTAssertio2.347 of 5 stars$0.76+4.7%$2.75+263.4%-27.9%$72.47M$124.96M-1.0420Positive NewsTHTXTheratechnologiesN/A$1.57-0.6%N/A-9.6%$72.19M$85.87M-15.70140Short Interest ↓High Trading VolumeANROAlto Neuroscience1.7138 of 5 stars$2.65-0.2%$16.75+533.3%-85.0%$71.34MN/A-1.04N/AGap DownSKYESkye Bioscience1.3978 of 5 stars$2.35+4.4%$18.00+666.0%-88.0%$71.29MN/A-3.2611ALGSAligos Therapeutics3.9748 of 5 stars$11.63+8.2%$70.00+501.9%-62.8%$71.11M$3.95M-0.8790News CoverageGap UpADAPAdaptimmune Therapeutics2.6798 of 5 stars$0.28-4.8%$2.18+687.6%-87.0%$70.83M$175.04M-1.26490Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpENTXEntera Bio2.454 of 5 stars$1.95flat$10.00+412.8%+4.8%$69.78M$99,000.00-7.5020Earnings ReportShort Interest ↓News CoverageIMABI-Mab2.6983 of 5 stars$0.87+2.0%$7.00+706.6%-54.8%$69.33M$3.27M0.00380Upcoming EarningsEPIXESSA Pharma2.8178 of 5 stars$1.56-1.3%$9.50+509.0%-81.6%$69.25MN/A-2.2650ALTSJanoneN/A$4.91+3.8%N/AN/A$69.08M$7.11M0.00170Short Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies ASRT Alternatives THTX Alternatives ANRO Alternatives SKYE Alternatives ALGS Alternatives ADAP Alternatives ENTX Alternatives IMAB Alternatives EPIX Alternatives ALTS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
